From the Scientific Team

Thirty years ago in October 1982, the FDA approved the sale to the public of the first recombinant protein drug, human insulin. In those thirty years much has changed. Molecular biosciences have undergone a revolution, such that what could only be dreamed of then is routine now, and recombinant protein drugs are used by millions of people every day. However, some things have not changed. Affordable healthcare is still only a distant dream for many people. Paras Biopharmaceuticals was established with the vision of using appropriate ideas from basic science, from academia, to produce protein therapeutics more efficiently; to make healthcare more affordable.

While a myriad of advances have been made in molecular biosciences, most are not applicable for production on an industrial scale. What works in an academic group to produce a few milligrams of protein is often not scalable to the production of kilograms amounts of protein. Through the active synergy of academic understanding with proven expertise in delivering industrial scale protein production to market, Paras Biopharmaceuticals aims to supply workable innovative solutions to a range of problems. In Paras Biopharmaceuticals R&D, we work on the principle - why have complications you can avoid? Rational design of processes combining academic and industrial expertise means increased efficiency without compromising quality. In Finnish Paras means best, but just as science is subtle so too is language and Paras has connotations of ultimate, optimal and pre-eminent. Paras Biopharmaceuticals aims to live up to its name.

At Paras Biopharmaceuticals science allows efficiency and quality to go hand in hand.

Yours Sincerely
The Scientific Team

Meet Us At

Connect with us

Paras Biopharmaceuticals
Finland Oy
,

Kiviharjunlenkki 10, OULU,
FI-90220 Finland

P: +358 442709462

Dr Ashesh Kumar
E: kumar.ashesh@parasbiopharma.com
P: +358 (0) 400207380

Dr Mark Jackson
E: mark.jackson@parasbiopharma.com
P:+358 (0) 442905993

Skype: Paras.Finland